Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FXS6837
Therapeutic Area : Immunology
Study Phase : Phase II
Recipient : Fosun Pharmaceutical
Deal Size : $670.0 million
Deal Type : Licensing Agreement
Forbion, OrbiMed-backed Sitala seals $670M deal for Fosun immune disease drug
Details : Under the licensing agreement, Sitala will hold the right of FXS6837, which is being evaluated for the treatment of immune disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $25.0 million
August 26, 2025
Lead Product(s) : FXS6837
Therapeutic Area : Immunology
Highest Development Status : Phase II
Recipient : Fosun Pharmaceutical
Deal Size : $670.0 million
Deal Type : Licensing Agreement